News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
613,174 Results
Type
Article (40792)
Company Profile (187)
Press Release (572183)
Multimedia
Podcasts (143)
Webinars (26)
Section
Business (180917)
Career Advice (2117)
Deals (29005)
Drug Delivery (122)
Drug Development (75295)
Employer Resources (141)
FDA (14102)
Job Trends (13025)
News (305389)
Policy (28189)
Tag
Academia (2249)
Academic (1)
Accelerated approval (15)
Adcomms (27)
Allergies (108)
Alliances (46769)
ALS (137)
Alzheimer's disease (1445)
Antibody-drug conjugate (ADC) (239)
Approvals (14204)
Artificial intelligence (433)
Autoimmune disease (89)
Automation (28)
Bankruptcy (263)
Best Places to Work (9994)
BIOSECURE Act (20)
Biosimilars (158)
Biotechnology (88)
Bladder cancer (132)
Brain cancer (46)
Breast cancer (459)
Cancer (3748)
Cardiovascular disease (328)
Career advice (1795)
Career pathing (34)
CAR-T (207)
CDC (35)
Cell therapy (593)
Cervical cancer (27)
Clinical research (63532)
Collaboration (1360)
Company closure (2)
Compensation (661)
Complete response letters (47)
COVID-19 (2275)
CRISPR (75)
C-suite (569)
Cystic fibrosis (127)
Data (4606)
Decentralized trials (2)
Denatured (47)
Depression (86)
Diabetes (417)
Diagnostics (5322)
Digital health (32)
Diversity (12)
Diversity, equity & inclusion (41)
Drug discovery (206)
Drug pricing (187)
Drug shortages (35)
Duchenne muscular dystrophy (183)
Earnings (74946)
Editorial (50)
Employer branding (18)
Employer resources (129)
Events (97512)
Executive appointments (916)
FDA (16418)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (3)
Frontotemporal dementia (14)
Funding (1124)
Gene editing (151)
Generative AI (42)
Gene therapy (486)
GLP-1 (919)
Government (3840)
Grass and pollen (7)
Guidances (350)
Healthcare (15210)
HIV (42)
Huntington's disease (34)
IgA nephropathy (59)
Immunology and inflammation (215)
Immuno-oncology (16)
Indications (56)
Infectious disease (2479)
Inflammatory bowel disease (171)
Inflation Reduction Act (14)
Influenza (84)
Intellectual property (180)
Interviews (381)
IPO (12929)
IRA (57)
Job creations (3402)
Job search strategy (1507)
Kidney cancer (13)
Labor market (66)
Layoffs (486)
Leadership (35)
Legal (6837)
Liver cancer (76)
Longevity (10)
Lung cancer (550)
Lymphoma (272)
Machine learning (28)
Management (47)
Manufacturing (601)
MASH (136)
Medical device (9792)
Medtech (9813)
Mergers & acquisitions (16927)
Metabolic disorders (1076)
Multiple sclerosis (131)
NASH (22)
Neurodegenerative disease (198)
Neuropsychiatric disorders (51)
Neuroscience (2397)
NextGen: Class of 2025 (5321)
Non-profit (3740)
Now hiring (49)
Obesity (521)
Opinion (291)
Ovarian cancer (126)
Pain (159)
Pancreatic cancer (156)
Parkinson's disease (226)
Partnered (23)
Patents (377)
Patient recruitment (304)
Peanut (42)
People (53731)
Pharmaceutical (85)
Pharmacy benefit managers (29)
Phase I (19886)
Phase II (27620)
Phase III (21178)
Pipeline (2689)
Policy (265)
Postmarket research (2439)
Preclinical (8373)
Press Release (59)
Prostate cancer (192)
Psychedelics (38)
Radiopharmaceuticals (255)
Rare diseases (614)
Real estate (5077)
Recruiting (59)
Regulatory (20669)
Reports (38)
Research institute (2197)
Resumes & cover letters (324)
Rett syndrome (15)
RNA editing (13)
RSV (62)
Schizophrenia (129)
Series A (194)
Series B (135)
Service/supplier (10)
Sickle cell disease (82)
Special edition (24)
Spinal muscular atrophy (140)
Sponsored (32)
Startups (3103)
State (2)
Stomach cancer (14)
Supply chain (92)
Tariffs (95)
The Weekly (94)
Vaccines (811)
Venture capital (58)
Weight loss (375)
Women's health (51)
Worklife (17)
Date
Today (248)
Last 7 days (743)
Last 30 days (2674)
Last 365 days (29106)
2025 (24375)
2024 (31705)
2023 (35170)
2022 (44941)
2021 (47873)
2020 (45944)
2019 (39505)
2018 (29957)
2017 (29114)
2016 (28459)
2015 (32740)
2014 (27054)
2013 (23335)
2012 (24055)
2011 (24097)
2010 (22491)
Location
Africa (786)
Alabama (77)
Alaska (6)
Arizona (187)
Arkansas (12)
Asia (38479)
Australia (5783)
California (8411)
Canada (2561)
China (853)
Colorado (366)
Connecticut (394)
Delaware (264)
Europe (83912)
Florida (1256)
Georgia (273)
Hawaii (2)
Idaho (39)
Illinois (686)
India (51)
Indiana (422)
Iowa (18)
Japan (327)
Kansas (106)
Kentucky (32)
Louisiana (13)
Maine (36)
Maryland (1087)
Massachusetts (6439)
Michigan (244)
Minnesota (438)
Mississippi (3)
Missouri (79)
Montana (22)
Nebraska (21)
Nevada (91)
New Hampshire (47)
New Jersey (2486)
New Mexico (29)
New York (2336)
North Carolina (1203)
North Dakota (10)
Northern California (3920)
Ohio (246)
Oklahoma (20)
Oregon (32)
Pennsylvania (1754)
Puerto Rico (18)
Rhode Island (38)
South America (1078)
South Carolina (35)
South Dakota (1)
Southern California (3285)
Tennessee (137)
Texas (1304)
United States (30993)
Utah (240)
Virginia (232)
Washington D.C. (77)
Washington State (706)
West Virginia (3)
Wisconsin (88)
Wyoming (2)
613,174 Results for "d and a pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nxera Pharma to Host R&D Day 2025
November 4, 2025
·
2 min read
Mergers & acquisitions
5 SMID-Cap Pharmas Poised for M&A Action
Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the small- to mid-cap pharmas best prepared to bolster their pipelines with a buyout.
October 29, 2025
·
7 min read
·
Annalee Armstrong
Editorial
GSK CEO Emma Walmsley’s Departure Reseals Pharma’s Glass Ceiling
After Emma Walmsley steps down as GSK CEO in January, Vertex Pharma’s Reshma Kewalramani will be the sole female CEO at a top-20 pharma company. Still, there are many prominent women in pharma that could someday break through again.
September 29, 2025
·
1 min read
·
Annalee Armstrong
Clinical research
Undeterred by Political, Economic Headwinds, Pharma Ups R&D Investment in 2024 and Beyond
R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.
May 28, 2025
·
12 min read
·
Tristan Manalac
Earnings
AstraZeneca CEO Says World ‘Needs to Share’ in Global Pharma R&D
Pascal Soriot’s comments came during AstraZeneca’s Q2 earnings call in regard to President Donald Trump’s newly announced European pharma tariffs. The company also announced estimate-beating earnings, with its cancer portfolio driving earnings despite clinical roadblocks.
July 29, 2025
·
3 min read
·
Tristan Manalac
C-suite
GSK’s Emma Walmsley, Pharma’s First Woman CEO, Steps Down After 9 Years
Chief Commerical Officer Luke Miels will replace outgoing GSK CEO Emma Walmsley at the U.K. pharma next year.
September 29, 2025
·
4 min read
·
Annalee Armstrong
Government
How the UK’s ‘Credibility Challenge’ Hinders Attempts To Reverse Pharma’s Flight
Talks between pharma and successive U.K. governments have failed to deliver the market access terms that the industry wants, contributing to a pullback in investment.
October 1, 2025
·
4 min read
·
Nick Paul Taylor
Opinion
Pharma Is Sitting on Hidden Cures. Find Your “Freda” To Unlock Them
Had Pfizer’s Freda Lewis-Hall not stepped in, SpringWorks’ rare disease treatment may never have reached patients. Pharmas can act now to help find the next Gomekli.
November 4, 2025
·
4 min read
·
Annette Bakker
Policy
NHS Mulls Greater Pharma Spending to Head Off Trump’s Tariffs: Report
The British proposal to increase support for pharma is “clearly positive,” according to analysts at Leerink, who noted that the NHS’ move will improve patient access to treatments.
October 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Redefining Pharmaceutical R&D Through AI and the Digitalized Physical DMTA Cycle
A major new two-part white paper series from ACD/Labs examines how AI-enabled design-make-test-analyze (DMTA) cycles can overcome fragmented workflows in drug discovery and development. The series discusses how pharma/biotech organizations can leverage automation and informatics technologies to digitalize workflows, empowering faster, robust, and more cost-effective innovation.
October 1, 2025
·
1 min read
1 of 61,318
Next